Wire · opportunities
Jazz's Ziihera secures 2nd survival win to solidify its HER2-positive stomach cancer status
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 1 September 2026 · Fusion42 review
Jazz Pharmaceuticals' Ziihera has achieved a second overall survival win in phase 3 trials, confirming its efficacy as a HER2-targeted therapy for first-line HER2-positive gastroesophageal adenocarcinoma, backed by recent FDA approval and strong market potential.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 25 Aug 2026 and 31 Aug 2026.
◆ ◆ The Wire takeaway
You can position your oncology drug development to target HER2-positive gastric cancers now that Ziihera has set a new survival standard and expanded commercial opportunity in the US. This changes competitive bar and could open doors for novel HER2 therapy adjuncts or safer combinations.
◆ Coverage
2 sources · first reported 25 Aug 2026 · latest 31 Aug 2026
◆ Related on Wire
◆ Topics